• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等
评价技术与方法

辛芳鼻炎胶囊中马兜铃酸Ⅰ测定方法研究及风险评估

  • 茹庆国 ,
  • 李海燕 ,
  • 刘亚楠 ,
  • 蒋芦荻 ,
  • 黄霞 ,
  • 王海波
展开
  • [河南省药品医疗器械检验院(河南省疫苗批签中心), 河南省中药质量控制工程研究中心, 河南 郑州 450018
茹庆国,男,硕士,主管中药师,研究方向:中药质量控制方法与质量评价

收稿日期: 2026-01-12

  修回日期: 2026-04-22

  录用日期: 2026-08-05

  网络出版日期: 2026-08-12

基金资助

 2023年国家药品抽检(中央补助地方经费项目);河南省市场监督管理局科技计划项目(HNSCJ GK202425)

Research on the Determination Method and Risk Assessment of Aristolochic Acid Ⅰin Xinfang Biyan Capsules

Expand
  • Henan Institute for Drug and Medical Device Control (Henan Vaccine Issuance Center),Henan Province Engineering Research Center of Quality Control of Traditional Chinese Medicine, Henan Zhengzhou 450018, China

Received date: 2026-01-12

  Revised date: 2026-04-22

  Accepted date: 2026-08-05

  Online published: 2026-08-12

摘要

目的:建立辛芳鼻炎胶囊中马兜铃酸Ⅰ的高效液相色谱-质谱测定法,为该品种安全性控制提供理论依据。方法:采用Waters ACQUITY UPLC HSS T3(2.1 mm×100 mm,1.8 μm)色谱柱,以甲醇-0.1%甲酸(含1 mmol·L-1乙酸铵)溶液为流动相,梯度洗脱,流速为0.3 mL·min-1,电喷雾离子源正离子模式,采用多反应监测,以外标法定量。结果:马兜铃酸Ⅰ在0.320 9~32.092 5 μg·mL-1范围内线性关系良好(r2=0.999 5),平均回收率为95.04%,104批样品均检出马兜铃酸Ⅰ,含量为7.91~90.75 ng·g-1。结论:该方法灵敏、准确、可靠,专属性强,可用于辛芳鼻炎胶囊中马兜铃酸Ⅰ的限量检查。

本文引用格式

茹庆国 , 李海燕 , 刘亚楠 , 蒋芦荻 , 黄霞 , 王海波 . 辛芳鼻炎胶囊中马兜铃酸Ⅰ测定方法研究及风险评估[J]. 中国药物评价, 2026 , 43(3) : 184 -184-188 . DOI: 10.2095-3593.2026.060001

Abstract

Objective: To establish an high performance liquid chromatography-mass spectrometry method for the determination of aristolochic acid Ⅰ in xinfang biyan capsules, and provide theoretical basis for its safety control. Methods:Waters ACQUITY UPLC HSS T3 (2.1 mm×100 mm, 1.8 μm) column was used. Methanol-0.1% formic acid (containing 1 mmol·L-1 ammonium acetate) solution was used as mobile phase, gradient elution, flow rate of 0.3 mL·min-1, positive ion mode of electric spray ion source, multi reaction monitoring, external standard determination. Results: The linear relationship of aristolochic acid I was good within the range of 0.320 9-32.092 5 μg·mL-1 (r2=0.999 5), with an average recovery rate of 95.04%. Aristolochic acid I was detected in all 104 batches of samples, with a content of 7.91-90.75 ng·g-1. Conclusion: This method is sensitive, accurate, reliable, and highly specific, and can be used for the limited detection of aristolochic acid I in xinfang biyan capsules.

参考文献

 [1] Sidorenko VS. Biotransformation and toxicities of aristolochic acids[J]. Adv Exp Med Biol, 2020, 1241:139-166.
     [2] World Health Organization International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans[M]. Lyon:IARC Press,2002.
     [3] ICHM7(R1) Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals of limit potential carcinogenic risk[EB/OL]. (2017-03-31).
     [4] Han J, Xian Z, Zhang Y, et al. Systematic overview of aristolochic acids: nephrotoxicity, carcinogenicity, and underlying mechanisms[J]. Frontiers in Pharmacology, 2019, 10:648.
     [5] 刘美婷, 王连嵋, 孟晶, 等. 细辛的化学成分、药理及毒理研究进展[J]. 中国实验方剂学杂志,2023,9(10):224-234.
     [6] 高月,肖小河,朱晓新,等. 马兜铃酸的毒性研究及思考[J]. 中国中药杂志,2017,42(21)∶ 4049-4053.
     [7] Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer Risk[J]. J Nat Cancer Institute, 2010, 102(3):179-86.
     [8] 原卫生部药典委员会. 中华人民共和国卫生部药品标准中药成方制剂第十五册[S]. 北京:人民卫生出版社,1998:97.
     [9] 原国家食品药品监督管理局. 国家药品标准(试行)YBZ16792006[S]. 北京:原国家食品药品监督管理局,2006.
     [10] 国家药典委员会. 中华人民共和国药典:一部[M]. 北京:中国医药科技出版社,2020:240-242.
     [11] 戴忠, 刘静, 郭日新, 等. 含马兜铃酸的中药现状及相关问题思考[J]. 中国现代中药,2024,26(8):1283-1293.
     [12] 史文慧, 王艳梅, 蒋黎, 等. 111例马兜铃酸肾病调查分析[J]. 药学实践与服务,2024,42(1):38-42.
文章导航

/